Alexion Pharmaceuticals Company Profile (NASDAQ:ALXN)

About Alexion Pharmaceuticals

Alexion Pharmaceuticals logoAlexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ALXN
  • CUSIP: 01535110
Key Metrics:
  • Previous Close: $130.44
  • 50 Day Moving Average: $132.05
  • 200 Day Moving Average: $126.86
  • 52-Week Range: $109.12 - $162.00
  • Trailing P/E Ratio: 74.11
  • Foreward P/E Ratio: 19.47
  • P/E Growth: 1.33
  • Market Cap: $29.30B
  • Outstanding Shares: 224,613,000
  • Beta: 1.39
  • Net Margins: 12.46%
  • Return on Equity: 10.58%
  • Return on Assets: 6.69%
  • Debt-to-Equity Ratio: 0.37%
  • Current Ratio: 2.51%
  • Quick Ratio: 2.16%
Additional Links:
Companies Related to Alexion Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Alexion Pharmaceuticals (NASDAQ:ALXN) (?)
Ratings Breakdown: 6 Hold Ratings, 16 Buy Ratings
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $170.33 (30.58% upside)

Analysts' Ratings History for Alexion Pharmaceuticals (NASDAQ:ALXN)
DateFirmActionRatingPrice TargetDetails
2/19/2017BMO Capital MarketsReiterated RatingOutperform$166.00 -> $158.00View Rating Details
2/16/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldView Rating Details
2/17/2017RBC Capital MarketsLower Price TargetOutperform$187.00 -> $177.00View Rating Details
2/17/2017Royal Bank of CanadaLower Price TargetOutperform$187.00 -> $177.00View Rating Details
2/17/2017Credit Suisse GroupReiterated RatingBuy$160.00View Rating Details
2/16/2017Cowen and CompanyReiterated RatingBuyView Rating Details
2/7/2017J P Morgan Chase & CoSet Price TargetBuy$170.00View Rating Details
1/7/2017Robert W. BairdReiterated RatingNeutral$145.00View Rating Details
1/6/2017Piper Jaffray CompaniesReiterated RatingBuy$176.00View Rating Details
12/25/2016Leerink SwannSet Price TargetBuy$211.00View Rating Details
12/25/2016Jefferies Group LLCSet Price TargetHold$120.00View Rating Details
12/23/2016Deutsche Bank AGReiterated RatingBuy$164.00 -> $160.00View Rating Details
12/13/2016WedbushReiterated RatingNeutral$135.00View Rating Details
12/13/2016Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details
11/30/2016FBR & CoReiterated RatingMarket Perform$130.00View Rating Details
11/29/2016Barclays PLCUpgradeEqual Weight -> Overweight$150.00 -> $155.00View Rating Details
11/10/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$158.00View Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$221.00View Rating Details
9/20/2016Citigroup Inc.Boost Price TargetBuy$154.00 -> $155.00View Rating Details
7/29/2016Stifel NicolausLower Price TargetBuy$195.00 -> $182.00View Rating Details
7/13/2016SunTrust Banks, Inc.Lower Price TargetBuy$220.00 -> $197.00View Rating Details
6/6/2016Bank of America CorpReiterated RatingBuyView Rating Details
1/7/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details
10/13/2015Raymond James Financial, Inc.Reiterated RatingStrong-Buy$225.00View Rating Details
6/23/2015Sanford C. BernsteinSet Price TargetBuy$267.00View Rating Details
5/7/2015NomuraUpgradeNeutral -> Buy$222.00 -> $246.00View Rating Details
(Data available from 2/24/2015 forward)


Earnings History for Alexion Pharmaceuticals (NASDAQ:ALXN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/16/2017Q416$1.25$1.26$840.69 million$831.00 millionViewN/AView Earnings Details
10/27/2016Q316$1.04$1.23$787.07 million$799.00 millionViewListenView Earnings Details
7/28/2016Q216$1.17$1.13$743.18 million$753.00 millionViewListenView Earnings Details
4/28/2016Q116$1.13$1.11$710.98 million$701.00 millionViewListenView Earnings Details
2/3/2016Q415$1.10$1.13$703.42 million$701.00 millionViewN/AView Earnings Details
10/29/2015Q315$1.01$1.16$668.33 million$666.60 millionViewListenView Earnings Details
7/30/2015Q215$1.39$1.44$628.03 million$636.00 millionViewListenView Earnings Details
4/23/2015Q115$1.32$1.28$594.40 million$600.30 millionViewN/AView Earnings Details
1/29/2015Q414$1.28$1.30$589.85 million$599.00 millionViewListenView Earnings Details
10/23/2014Q314$1.16$1.27$541.93 million$555.10 millionViewListenView Earnings Details
7/24/2014Q214$1.07$1.12$509.54 million$512.50 millionViewListenView Earnings Details
4/24/2014Q114$1.26$1.53$560.22 million$566.60 millionViewListenView Earnings Details
1/30/2014Q413$0.83$0.87$430.08 million$441.90 millionViewListenView Earnings Details
10/24/2013Q313$0.79$0.83$395.10 million$400.40 millionViewListenView Earnings Details
7/25/2013Q2 2013$0.68$0.73$364.80 million$370.10 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.61$0.65$336.56 million$338.90 millionViewListenView Earnings Details
2/14/2013Q4 2012$0.52$0.60$316.49 million$320.50 millionViewListenView Earnings Details
10/24/2012$0.47$0.60ViewN/AView Earnings Details
7/25/2012$0.36$0.47ViewN/AView Earnings Details
4/24/2012$0.38$0.45ViewN/AView Earnings Details
2/9/2012$0.33$0.41ViewN/AView Earnings Details
10/20/2011$0.28$0.37ViewN/AView Earnings Details
7/21/2011$0.26$0.29ViewN/AView Earnings Details
4/21/2011$0.51$0.59ViewN/AView Earnings Details
2/10/2011$0.50$0.51ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alexion Pharmaceuticals (NASDAQ:ALXN)
Current Year EPS Consensus Estimate: $5.28 EPS
Next Year EPS Consensus Estimate: $6.70 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.91$0.91$0.91
Q2 20161$1.07$1.07$1.07
Q3 20161$1.17$1.17$1.17
Q4 20161$1.28$1.28$1.28
(Data provided by Zacks Investment Research)


Dividend History for Alexion Pharmaceuticals (NASDAQ:ALXN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Alexion Pharmaceuticals (NASDAQ:ALXN)
Insider Ownership Percentage: 4.41%
Institutional Ownership Percentage: 94.98%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/9/2017John B MoriartyEVPSell167$126.84$21,182.28View SEC Filing  
2/9/2017Leonard BellDirectorSell246$126.84$31,202.64View SEC Filing  
2/7/2017Heidi L WagnerSVPSell1,932$125.97$243,374.04View SEC Filing  
2/7/2017John B MoriartyEVPSell3,538$125.79$445,045.02View SEC Filing  
2/7/2017Leonard BellDirectorSell8,725$125.97$1,099,088.25View SEC Filing  
1/10/2017Leonard BellDirectorSell100$144.99$14,499.00View SEC Filing  
1/9/2017Leonard BellDirectorSell40,065$138.48$5,548,201.20View SEC Filing  
1/5/2017Alvin S ParvenDirectorSell22,659$138.35$3,134,872.65View SEC Filing  
12/12/2016John B MoriartyEVPSell1,044$118.61$123,828.84View SEC Filing  
12/9/2016Carsten ThielEVPSell2,308$130.00$300,040.00View SEC Filing  
11/14/2016Heidi L WagnerSVPSell59$115.10$6,790.90View SEC Filing  
11/4/2016Leonard BellDirectorSell37,317$140.38$5,238,560.46View SEC Filing  
10/31/2016Leonard BellDirectorSell1,300$135.28$175,864.00View SEC Filing  
10/14/2016Carsten ThielEVPSell4,584$120.28$551,363.52View SEC Filing  
10/3/2016Carsten ThielEVPSell29$122.41$3,549.89View SEC Filing  
10/3/2016Heidi L WagnerSVPSell120$122.41$14,689.20View SEC Filing  
9/13/2016Carsten ThielEVPSell3,225$128.67$414,960.75View SEC Filing  
9/9/2016Edward MillerSVPSell367$128.32$47,093.44View SEC Filing  
9/6/2016Carsten ThielEVPSell1,000$125.94$125,940.00View SEC Filing  
9/2/2016Julie O'neillEVPSell650$126.29$82,088.50View SEC Filing  
8/30/2016Clare CarmichaelEVPSell1,000$127.76$127,760.00View SEC Filing  
8/22/2016Alvin S ParvenDirectorSell15,000$136.53$2,047,950.00View SEC Filing  
8/15/2016Alvin S ParvenDirectorSell700$135.51$94,857.00View SEC Filing  
8/8/2016Clare CarmichaelEVPSell165$137.14$22,628.10View SEC Filing  
8/8/2016David HallalCEOSell332$137.14$45,530.48View SEC Filing  
8/8/2016Heidi L WagnerSVPSell222$137.14$30,445.08View SEC Filing  
8/8/2016Leonard BellDirectorSell1,010$137.14$138,511.40View SEC Filing  
8/8/2016Vikas SinhaCFOSell277$137.14$37,987.78View SEC Filing  
6/13/2016John B MoriartyEVPSell918$135.72$124,590.96View SEC Filing  
5/16/2016Martin MackayEVPSell4,097$139.20$570,302.40View SEC Filing  
5/13/2016Heidi L WagnerSVPSell53$138.65$7,348.45View SEC Filing  
4/1/2016David HallalCEOSell1,414$135.88$192,134.32View SEC Filing  
2/29/2016Clare CarmichaelEVPSell1,312$138.91$182,249.92View SEC Filing  
2/29/2016David HallalCEOSell2,014$138.93$279,805.02View SEC Filing  
2/29/2016Edward MillerSVPSell329$138.91$45,701.39View SEC Filing  
2/29/2016Leonard BellDirectorSell3,995$138.92$554,985.40View SEC Filing  
2/29/2016Vikas SinhaCFOSell1,122$138.91$155,857.02View SEC Filing  
2/8/2016David HallalCEOSell11,297$140.50$1,587,228.50View SEC Filing  
2/8/2016Heidi L. WagnerSVPSell2,108$140.93$297,080.44View SEC Filing  
2/8/2016Julie O'neillEVPSell2,858$141.83$405,350.14View SEC Filing  
2/8/2016Leonard BellDirectorSell15,872$139.58$2,215,413.76View SEC Filing  
2/8/2016Vikas SinhaCFOSell6,547$140.04$916,841.88View SEC Filing  
2/5/2016Edward MillerSVPSell1,051$143.02$150,314.02View SEC Filing  
12/29/2015Leonard BellDirectorSell35,000$190.66$6,673,100.00View SEC Filing  
12/17/2015Leonard BellDirectorSell70,000$187.69$13,138,300.00View SEC Filing  
12/11/2015Ann M VenemanDirectorSell895$187.48$167,794.60View SEC Filing  
12/11/2015John B. MoriartyEVPSell943$182.73$172,314.39View SEC Filing  
12/8/2015Leonard BellDirectorSell70,000$188.20$13,174,000.00View SEC Filing  
12/8/2015Saqib IslamEVPSell950$190.00$180,500.00View SEC Filing  
11/25/2015Leonard BellDirectorSell35,000$181.89$6,366,150.00View SEC Filing  
10/26/2015Saqib IslamEVPSell1,558$168.44$262,429.52View SEC Filing  
9/9/2015Leonard BellDirectorSell1,050$180.10$189,105.00View SEC Filing  
6/18/2015Leonard BellDirectorSell27,835$179.63$5,000,001.05View SEC Filing  
3/19/2015Leonard BellCEOSell15,952$188.07$3,000,092.64View SEC Filing  
3/2/2015Julie O'neillEVPSell11,665$101.49$1,183,880.85View SEC Filing  
3/2/2015Leonard BellCEOSell1,230$180.34$221,818.20View SEC Filing  
2/10/2015Clare CarmichaelEVPSell1,490$171.15$255,013.50View SEC Filing  
2/10/2015David HallalCOOSell1,980$171.15$338,877.00View SEC Filing  
2/10/2015Leonard BellCEOSell5,740$171.15$982,401.00View SEC Filing  
2/10/2015Vikas SinhaCFOSell1,985$171.15$339,732.75View SEC Filing  
2/9/2015Clare CarmichaelEVPSell1,665$173.75$289,293.75View SEC Filing  
2/9/2015David HallalCOOSell2,920$173.93$507,875.60View SEC Filing  
2/9/2015Leonard BellCEOSell8,660$173.98$1,506,666.80View SEC Filing  
2/9/2015Vikas SinhaCFOSell2,703$174.18$470,808.54View SEC Filing  
2/4/2015David HallalCOOSell1,373$174.18$239,149.14View SEC Filing  
2/4/2015Leonard BellCEOSell5,223$174.29$910,316.67View SEC Filing  
2/4/2015Vikas SinhaCFOSell1,571$174.19$273,652.49View SEC Filing  
12/18/2014David HallalCOOSell5,494$182.03$1,000,072.82View SEC Filing  
12/18/2014Leonard BellCEOSell30,415$179.73$5,466,487.95View SEC Filing  
12/18/2014Vikas SinhaCFOSell5,493$182.08$1,000,165.44View SEC Filing  
12/9/2014Leonard BellCEOSell133,320$198.26$26,432,023.20View SEC Filing  
12/4/2014Clare CarmichaelSVPSell10,000$196.25$1,962,500.00View SEC Filing  
12/4/2014William R KellerDirectorSell5,000$196.25$981,250.00View SEC Filing  
12/3/2014Vikas SinhaCFOSell75,000$198.96$14,922,000.00View SEC Filing  
11/3/2014David HallalCOOSell30,000$190.01$5,700,300.00View SEC Filing  
11/3/2014Martin MackayEVPSell9,375$191.52$1,795,500.00View SEC Filing  
11/3/2014Saqib IslamSVPSell28,125$190.50$5,357,812.50View SEC Filing  
11/3/2014Vikas SinhaCFOSell49,307$192.63$9,498,007.41View SEC Filing  
10/27/2014John B MoriartySVPSell10,000$189.49$1,894,900.00View SEC Filing  
10/27/2014Stephen P SquintoEVPSell5,910$188.58$1,114,507.80View SEC Filing  
10/6/2014John B MoriartySVPSell10,000$179.00$1,790,000.00View SEC Filing  
10/3/2014Stephen P SquintoEVPSell10,025$172.41$1,728,410.25View SEC Filing  
9/26/2014Leonard BellCEOSell60,000$165.12$9,907,200.00View SEC Filing  
9/24/2014Stephen P SquintoEVPSell76$159.50$12,122.00View SEC Filing  
9/18/2014Leonard BellCEOSell44,435$160.60$7,136,261.00View SEC Filing  
9/10/2014Leonard BellCEOSell12,199$165.38$2,017,470.62View SEC Filing  
9/8/2014Leonard BellCEOSell197,801$165.32$32,700,461.32View SEC Filing  
8/27/2014Leonard BellCEOSell5,912$169.17$1,000,133.04View SEC Filing  
8/25/2014Andreas RummeltDirectorSell5,052$170.53$861,517.56View SEC Filing  
8/15/2014Leonard BellCEOSell70,000$167.99$11,759,300.00View SEC Filing  
8/13/2014Leonard BellCEOSell105,000$160.71$16,874,550.00View SEC Filing  
8/12/2014Leonard BellCEOSell80,458$160.16$12,886,153.28View SEC Filing  
8/4/2014David HallalEVPSell1,349$158.00$213,142.00View SEC Filing  
8/4/2014Leonard BellCEOSell5,145$157.88$812,292.60View SEC Filing  
8/4/2014Vikas SinhaCFOSell1,525$157.82$240,675.50View SEC Filing  
7/30/2014Leonard BellCEOSell127,289$162.93$20,739,196.77View SEC Filing  
7/29/2014Leonard BellCEOSell1,200$164.93$197,916.00View SEC Filing  
7/28/2014Leonard BellCEOSell105,600$162.38$17,147,328.00View SEC Filing  
6/20/2014Leonard BellCEOSell90,280$163.60$14,769,808.00View SEC Filing  
6/12/2014Martin MackayEVPSell25,000$166.42$4,160,500.00View SEC Filing  
6/5/2014William R KellerDirectorSell3,425$170.00$582,250.00View SEC Filing  
5/27/2014Leonard BellCEOSell70,000$166.16$11,631,200.00View SEC Filing  
5/20/2014Leonard BellCEOSell70,000$155.96$10,917,200.00View SEC Filing  
5/14/2014Martin MackayEVPSell3,574$160.85$574,877.90View SEC Filing  
5/13/2014Alvin ParvenDirectorSell12,276$160.78$1,973,735.28View SEC Filing  
4/29/2014Leonard BellCEOSell70,000$156.20$10,934,000.00View SEC Filing  
2/10/2014Stephen SquintoEVPSell7,055$158.04$1,114,972.20View SEC Filing  
2/7/2014David HallalEVPSell1,620$155.57$252,023.40View SEC Filing  
2/7/2014Frank WrightSVPSell1,098$155.57$170,815.86View SEC Filing  
2/7/2014Joseph MadriDirectorSell30,000$159.00$4,770,000.00View SEC Filing  
2/7/2014Leonard BellCEOSell4,620$155.56$718,687.20View SEC Filing  
2/4/2014Leonard BellCEOSell11,790$154.50$1,821,555.00View SEC Filing  
2/4/2014Stephen SquintoEVPSell36,989$155.12$5,737,733.68View SEC Filing  
2/4/2014Vikas SinhaCFOSell3,552$154.47$548,677.44View SEC Filing  
1/29/2014Leonard BellCEOSell2,660$133.81$355,934.60View SEC Filing  
1/29/2014Stephen SquintoEVPSell1,118$133.31$149,040.58View SEC Filing  
1/22/2014Leonard BellCEOSell156,436$140.80$22,026,188.80View SEC Filing  
1/10/2014Leonard BellCEOSell19,155$134.98$2,585,541.90View SEC Filing  
12/19/2013Leonard BellCEOSell175,000$126.38$22,116,500.00View SEC Filing  
10/28/2013Stephen P SquintoEVPSell41,037$124.06$5,091,050.22View SEC Filing  
10/28/2013Vikas SinhaCFOSell50,000$122.97$6,148,500.00View SEC Filing  
9/16/2013Joseph MadriDirectorSell30,000$115.00$3,450,000.00View SEC Filing  
9/16/2013Leonard BellCEOSell3,500$115.00$402,500.00View SEC Filing  
9/13/2013Stephen SquintoEVPSell1,000$114.37$114,370.00View SEC Filing  
9/4/2013Leonard BellCEOSell1,850$110.07$203,629.50View SEC Filing  
9/3/2013Leonard BellCEOSell33,150$110.19$3,652,798.50View SEC Filing  
8/30/2013Clare CarmichaelSVPSell1,237$107.58$133,076.46View SEC Filing  
8/16/2013Leonard BellCEOSell140,000$106.08$14,851,200.00View SEC Filing  
8/5/2013Leonard BellCEOSell2,919$116.87$341,143.53View SEC Filing  
8/2/2013Stephen P SquintoEVPSell14,125$115.33$1,629,036.25View SEC Filing  
7/30/2013Leonard BellCEOSell212,737$114.62$24,383,914.94View SEC Filing  
7/30/2013Stephen P SquintoEVPSell1,120$110.86$124,163.20View SEC Filing  
7/12/2013David HallalEVPSell50,000$120.00$6,000,000.00View SEC Filing  
7/1/2013Stephen P SquintoEVPSell44,125$94.97$4,190,551.25View SEC Filing  
5/22/2013R Douglas NorbyDirectorSell40,000$102.77$4,110,800.00View SEC Filing  
5/20/2013William R KellerDirectorSell9,770$103.00$1,006,310.00View SEC Filing  
5/14/2013Leonard BellCEOSell31,113$105.74$3,289,888.62View SEC Filing  
5/13/2013Leonard BellCEOSell41,220$100.85$4,157,037.00View SEC Filing  
4/10/2013Leonard BellCEOSell26,700$100.24$2,676,408.00View SEC Filing  
2/4/2013Leonard BellCEOSell11,880$96.27$1,143,687.60View SEC Filing  
2/4/2013Stephen P SquintoEVPSell2,572$95.68$246,088.96View SEC Filing  
2/4/2013Vikas SinhaCFOSell3,483$95.81$333,706.23View SEC Filing  
1/15/2013Leonard BellCEOSell35,000$98.58$3,450,300.00View SEC Filing  
10/31/2012Patrice CoissacSVPSell84,764$91.16$7,727,086.24View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Alexion Pharmaceuticals (NASDAQ:ALXN)
News IconAnalysts Peeling Back The Layers on Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN): Consensus Take - Winfield Review (NASDAQ:ALXN) - February 23 at 8:31 PM
News IconIs It Time to go for Alexion Pharmaceuticals, Inc. (ALXN), CH Robinson Worldwide, Inc. (CHRW)? - StockNewsJournal (NASDAQ:ALXN) - February 23 at 3:30 PM
News IconEye on Technical Levels for Alexion Pharmaceuticals Inc (ALXN) - SKV News (NASDAQ:ALXN) - February 22 at 8:33 PM
News IconChurch & Dwight Co., Inc. (CHD), Alexion Pharmaceuticals, Inc. (ALXN) Stock Eyes Ahead of Earnings - The USA Commerce (NASDAQ:ALXN) - February 22 at 3:31 PM logoALEXION PHARMACEUTICALS INC Financials (NASDAQ:ALXN) - February 22 at 3:31 PM
News IconTop Gainers of the Day: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) from Biotechnology (NASDAQ:ALXN) - February 22 at 11:33 AM
News IconA Keen Look At The Chart For Alexion Pharmaceuticals, Inc. (ALXN) - NY Stock News (NASDAQ:ALXN) - February 21 at 3:46 PM
News IconRevenue Approximations Analysis: Alexion Pharmaceuticals, Inc. (ALXN), Las Vegas Sands Corp. (LVS) - StockNewsJournal (NASDAQ:ALXN) - February 21 at 3:46 PM logoAlexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: 2016 By the Numbers : February 21, 2017 (NASDAQ:ALXN) - February 21 at 3:46 PM
News IconBuy, Sell or Hold? Analysts Approach: Alexion Pharmaceuticals, Inc. (ALXN), Las Vegas Sands Corp. (LVS)? - The USA Commerce (NASDAQ:ALXN) - February 21 at 7:16 AM logoAlexion Shelves Rare-Disease Drug SBC-103 (ALXN) (NASDAQ:ALXN) - February 20 at 3:26 PM logoAlexion Halts Rare-Disease Drug SBC-103 Program (NASDAQ:ALXN) - February 20 at 3:26 PM logoForget Alexion, Buy these 4 Biotech Stocks Instead (NASDAQ:ALXN) - February 20 at 7:04 AM logoTough U.K. Line on Rare-Disease Drugs Stirs Concern After Brexit (NASDAQ:ALXN) - February 20 at 7:04 AM
News IconThe Technical Case for and Against Alexion Pharmaceuticals (ALXN) - The USA Commerce (NASDAQ:ALXN) - February 18 at 9:36 AM logoAlexion (ALXN) Misses on Q4 Earnings and Revenues - Nasdaq (NASDAQ:ALXN) - February 18 at 9:36 AM logoAlexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Suffers Another Blow In The UK (NASDAQ:ALXN) - February 17 at 6:37 PM logoEdited Transcript of ALXN earnings conference call or presentation 16-Feb-17 3:00pm GMT (NASDAQ:ALXN) - February 17 at 6:37 PM logo[$$] Takeover Candidate Alexion Is on the Mend (NASDAQ:ALXN) - February 17 at 6:37 PM logoAlexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 17, 2017 (NASDAQ:ALXN) - February 17 at 6:37 PM
News IconAlexion Pharmaceuticals, Inc. (ALXN) Suffers Another Blow In The UK (NASDAQ:ALXN) - February 17 at 1:28 PM logoAlexion Expands Share Buyback; Sees FY17 Results Below View (NASDAQ:ALXN) - February 16 at 8:34 PM
News IconYTD Performance of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) stands at 4.43% (NASDAQ:ALXN) - February 16 at 8:34 PM
News IconYTD Performance of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) stands at 4.43% (NASDAQ:ALXN) - February 16 at 8:34 PM
News IconYTD Performance of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) stands at 4.43% (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion Pharma's revenue rises 18.5 percent (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion Pharma's revenue rises 18.5 percent (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion Pharma's revenue rises 18.5 percent (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion Pharmaceuticals Inc. Bottom Line Advances 20% In Q4 (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion Pharmaceuticals Inc. Bottom Line Advances 20% In Q4 (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion Pharmaceuticals Inc. Bottom Line Advances 20% In Q4 (NASDAQ:ALXN) - February 16 at 8:34 PM
News IconAlexion Pharmaceuticals, Inc. (ALXN) Updates FY17 Earnings Guidance (NASDAQ:ALXN) - February 16 at 8:34 PM
News IconAlexion Pharmaceuticals, Inc. (ALXN) Updates FY17 Earnings Guidance (NASDAQ:ALXN) - February 16 at 8:34 PM
News IconAlexion Pharmaceuticals, Inc. (ALXN) Updates FY17 Earnings Guidance (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion Pharmaceuticals (ALXN) Q4 2016 Results - Earnings Call Transcript (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion Pharmaceuticals (ALXN) Q4 2016 Results - Earnings Call Transcript (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion Pharmaceuticals (ALXN) Q4 2016 Results - Earnings Call Transcript (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion Pharmaceuticals on the Recovery Trail (ALXN) (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion Pharmaceuticals on the Recovery Trail (ALXN) (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion Pharmaceuticals on the Recovery Trail (ALXN) (NASDAQ:ALXN) - February 16 at 8:34 PM logoHow Alexion’s Pipeline Is Driving Earnings (NASDAQ:ALXN) - February 16 at 8:34 PM logoHow Alexion’s Pipeline Is Driving Earnings (NASDAQ:ALXN) - February 16 at 8:34 PM logoHow Alexion’s Pipeline Is Driving Earnings (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion’s Kanuma Drug Denied UK Approval (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion’s Kanuma Drug Denied UK Approval (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion’s Kanuma Drug Denied UK Approval (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion 4Q Earnings of $1.26 a Share Beats Street (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion 4Q Earnings of $1.26 a Share Beats Street (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion 4Q Earnings of $1.26 a Share Beats Street (NASDAQ:ALXN) - February 16 at 8:34 PM logoAlexion (ALXN) Misses on Q4 Earnings and Revenues (NASDAQ:ALXN) - February 16 at 8:34 PM


What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Where is Alexion Pharmaceuticals' stock going? Where will Alexion Pharmaceuticals' stock price be in 2017?

22 analysts have issued 12 month price objectives for Alexion Pharmaceuticals' shares. Their predictions range from $120.00 to $221.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $170.33 in the next twelve months.

When will Alexion Pharmaceuticals announce their earnings?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

What are analysts saying about Alexion Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:

  • RBC Capital Markets analysts commented, "Two new Phase III trials of ALXN1210 in PNH and aHUS announced; subQ formulation with 'new higher concentration formulation' mentioned on the call: On the second page of today's press release, Alexion disclosed the initiation of a new Phase III switch study of '1210 in PNH: 192 PNH patients who have been treated with Soliris will be enrolled into this openlabel, randomized (1:1), 26-week study. The study will compare patients receiving Q8W dosing of '1210 and Soliris on 3 weight cohorts. The primary endpoint is % change in LDH levels. Enrollment for this study will begin in 2Q17. In addition, a second Phase III trial of F1210 in pediatric aHUS is planned to start in 2Q17. Management reiterated that the target approval timing for ALXN1210 is late 2018 or early 2019. In addition, enrollment of 40 healthy volunteers in the Phase I trial of subcutaneous ALXN1210 was completed in 4Q16' Adjusting PT following SBC-103 discontinuation/pipeline update: We have updated our model and have removed SBC-103 from our revenue model. We've also removed ALXN1007 for APS and GI-GvHD from our PAT revenue model, since it's no longer being mentioned in ALXN's slides. Our price target goes to $177 from $187." (2/17/2017)
  • Cowen and Company analysts commented, "Alexion reported Q4 revenues of $831MM (+19% Y/Y, vs. consensus of $836MM)." (2/16/2017)

  • According to Zacks Investment Research, "Alexion’s top-line continues to be driven by continued growth in Soliris across geographies, robust launch momentum of Strensiq in initial countries, and early contribution from the launch of Kanuma in the U.S. and Germany. In fact, the company is viewing Strensiq as a key growth driver in 2017 and beyond. Alexion also updated its 2016 guidance for revenues and earnings. The company expects to meet the high end of both the previously guided projections. Meanwhile, Alexion has quite a few candidates in its pipeline and is working on expanding Soliris’ label. However, the company has suffered some pipeline-related setbacks of late. Moreover, ongoing focus on drug pricing and sudden departure of its key executives in the middle of an ongoing internal probe into the sales practices related to Soliris are concerns. In fact, shares of Alexion have underperformed the Medical-Biomedical/Genetics industry year to date." (12/28/2016)

  • Piper Jaffray Companies analysts commented, "2017 outlook strong. CNC’s initial 2017 guidance for adjusted diluted EPS is $4.40-4.85, which is below our prior $5.00 estimate (now reduced to $4.90) primarily because the company assumes a 1.5% lower margins ($0.20 per share) than it earned in 2016, albeit on higher revenue. This translates into guidance of $4.60-$5.05 before these lower assumptions. Revenue guidance is $46-46.8 billion, in line with our $46.2 billion estimate, which assumes 0%-1% Medicaid rate increases and Medicare Advantage expansion in four states." (12/23/2016)

Who owns Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (12.58%), State Street Corp (4.72%), Sands Capital Management LLC (2.49%), Brown Advisory Inc. (1.45%), Franklin Resources Inc. (0.92%) and Temasek Holdings Private Ltd (0.55%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Carsten Thiel, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Martin Mackay, Saqib Islam and Vikas Sinha.

Who sold Alexion Pharmaceuticals stock? Who is selling Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Marshall Wace LLP, Calamos Advisors LLC, Tudor Investment Corp Et Al, Raymond James Financial Services Advisors Inc., Guggenheim Capital LLC, DSM Capital Partners LLC and TCW Group Inc.. Company insiders that have sold Alexion Pharmaceuticals stock in the last year include Alvin S Parven, Carsten Thiel, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Martin Mackay and Vikas Sinha.

Who bought Alexion Pharmaceuticals stock? Who is buying Alexion Pharmaceuticals stock?

Alexion Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., State Street Corp, Sands Capital Management LLC, Alyeska Investment Group L.P., Asset Management One Co. Ltd., Fred Alger Management Inc. and AMF Pensionsforsakring AB.

How do I buy Alexion Pharmaceuticals stock?

Shares of Alexion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Alexion Pharmaceuticals stock cost?

One share of Alexion Pharmaceuticals stock can currently be purchased for approximately $130.44.

Alexion Pharmaceuticals (NASDAQ:ALXN) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Earnings History Chart

Earnings by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Dividend History Chart

Dividend Payments by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Last Updated on 2/24/2017 by Staff